Sustained Treatment with Insulin Detemir in Mice Alters Brain Activity and Locomotion. [PDF]
PLoS ONE, 2016 AIMS:Recent studies have identified unique brain effects of insulin detemir (Levemir®). Due to its pharmacologic properties, insulin detemir may reach higher concentrations in the brain than regular insulin.
Tina Sartorius +3 more
doaj +2 more sources
Comparative study of the usefulness of a novel insulin therapy in Japanese patients with Type 2 diabetes for concomitant use of an oral antidiabetic agent with twice-daily dosing either of insulin aspart, biphasic insulin aspart-30, or insulin detemir: Two times Insulin injection Combined with oral therapy Efficacy Study (TWICE study) [PDF]
Fujita Medical Journal, 2021 Objectives: It is common to treat type 2 diabetes by regular injections of insulin. We compared the efficacy and safety of twice-daily administration of short-acting, premixed, and long-acting insulins.
Mitsuyasu Itoh +9 more
doaj +2 more sources
The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus [PDF]
Diabetology & Metabolic Syndrome, 2017 Background Type II diabetes is an important health problem with a complex connection to obesity, leading to a broad range of cardiovascular complications.
Tomislav Bozek +8 more
doaj +2 more sources
Effects of exogenous detemir and glargine insulin on the detection of endogenous C-peptide and endogenous insulin [PDF]
European Journal of Medical ResearchAims To examine the effects of administering detemir and glargine insulin on the detection of endogenous C-peptide and insulin levels. Methods This study enrolled 69 patients with type 2 diabetes (T2DM) who use long-acting insulin therapy.
Yi-ting Wang +4 more
doaj +2 more sources
Adiponectin, Leptin, and Leptin Receptor in Obese Patients with Type 2 Diabetes Treated with Insulin Detemir [PDF]
Molecules, 2017 The aim of the present study is to quantitatively assess the expression of selected regulatory molecules, such as leptin, leptin receptor, and adiponectin in the blood of obese patients with type 2 diabetes both before treatment and after six months of ...
Paweł Olczyk +9 more
doaj +2 more sources
Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial. [PDF]
PLoS ONE, 2014 Studies in rodents have demonstrated that insulin in the central nervous system induces satiety. In humans, these effects are less well established.
Larissa W van Golen +7 more
doaj +1 more source
BMC Endocrine Disorders, 2012 Background The uncertainties regarding dose similarities between basal long-acting insulin analogues remain. Recent real-world studies indicate dose similarities between insulin detemir and insulin glargine, but further studies are still warranted.
Jakobsen Marie +3 more
doaj +1 more source
Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
Clinical Medicine Insights: Endocrinology and Diabetes, 2010 Insulin detemir is a long-acting basal insulin approved for use in patients with type 1 (T1DM) or type 2 diabetes (T2DM). Insulin detemir has demonstrated equivalent glycemic control and hypoglycemic risk when compared to insulin glargine, and insulin ...
Jason R. Young, Carrie Mcadam-Marx
doaj +1 more source
Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
Сахарный диабет, 2017 Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin.
Lyudmila Alexandrovna Ruyatkina +1 more
doaj +1 more source
Cerebrocortical beta activity in overweight humans responds to insulin detemir.
PLoS ONE, 2007 BackgroundInsulin stimulates cerebrocortical beta and theta activity in lean humans. This effect is reduced in obese individuals indicating cerebrocortical insulin resistance.
Otto Tschritter +9 more
doaj +1 more source